Revenue
2020
2021
2022
2023
2024
2025
Elicio Therapeutics, Inc. (ELTX)
Price$1.83Cached quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $2.3M | $27.5M | $193,000 |
| Gross profit | — | — | — | $2.3M | $27.1M | −$997,000 |
| Gross margin | — | — | — | 100.00% | 98.43% | −516.58% |
| Research & development | $24.9M | $33.7M | $23.8M | $18.1M | $48.7M | $39.0M |
| Operating expenses | $37.3M | $45.0M | $35.7M | $26.0M | $66.4M | $54.3M |
| Operating income | −$37.7M | −$45.0M | −$35.7M | −$23.7M | −$39.3M | −$55.3M |
| Operating margin | — | — | — | −1,031.42% | −142.90% | −28,638.86% |
| EBITDA | −$37.5M | −$44.7M | −$35.4M | −$23.3M | −$39.2M | −$55.2M |
| EBITDA margin | — | — | — | −1,014.47% | −142.57% | −28,588.08% |
| Net income | −$39.6M | −$51.9M | −$35.2M | −$28.2M | −$54.6M | −$80.1M |
| Net profit margin | — | — | — | −1,225.90% | −198.40% | −41,506.22% |
| Basic EPSper basic share | -$2.58 | -$4.25 | -$6.96 | -$89.27 | -$181.42 | -$510.42 |
| Diluted EPSper diluted share | -$2.58 | -$4.25 | -$6.96 | -$89.27 | -$181.42 | -$510.42 |
Owners
Reported shareholders
≈24.73%of listed shares
Chudnovsky Yekaterina / GKCC, LLC5.42M shares · Mar 5, 2025
View holders
| Holder | % owned |
|---|---|
Chudnovsky Yekaterina / GKCC, LLC | ≈24.73%5.42M shares |
Knoll Capital Management, LLC | 5.53%1.21M shares |
BlackRock, Inc. | 3.50%766.01K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 2.61%572.15K shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.42%311.35K shares |
Venkatesan Jay | ≈0.82%180.53K shares |
STATE STREET CORP | 0.82%179.42K shares |
NORTHERN TRUST CORP | 0.59%130.16K shares |
Connelly Robert | ≈0.55%120.57K shares |
Ikarian Capital, LLC | 0.46%100K shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 0.41%88.91K shares |
VANGUARD FIDUCIARY TRUST CO | 0.40%88.06K shares |
ALLIANCEBERNSTEIN L.P. | 0.37%81.28K shares |
Haqq Christopher | ≈0.26%57.38K shares |
UBS Group AG | 0.18%40.42K shares |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.14%31.71K shares |
BOOTHBAY FUND MANAGEMENT, LLC | 0.14%30.69K shares |
MORGAN STANLEY | 0.12%25.55K shares |
Shah Preetam | ≈0.11%24K shares |
DeMuth Peter | ≈0.10%21.54K shares |
Percentages use 21.9M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Aug 12, 2024Form 4 | Chudnovsky Yekaterina +1Director,TenPercentOwner | BuyConvertible Note (convertible into Common Stock) · derivative · indirect | 3.44M | $5.81 | $20.00M | 3.44M |
| Jun 28, 2024Form 4/A | Venkatesan JayDirector | BuyPre-Funded Warrants · derivative | 50.0K | $4.99 | $249.5K | 50.0K |
| Jun 28, 2024Form 4/A | Venkatesan JayDirector | BuyCommon Warrants · derivative | 50.0K | $0.00 | $0.00 | 50.0K |
| Jun 28, 2024Form 4 | Venkatesan JayDirector | BuyPre-Funded Warrants · derivative · indirect | 50.0K | $4.99 | $249.5K | 50.0K |
| Jun 28, 2024Form 4 | Venkatesan JayDirector | BuyCommon Warrants · derivative · indirect | 50.0K | $0.00 | $0.00 | 50.0K |